osimertinib
aura biosciences,astrazeneca
['adaura', 'aura ,(-laura)']
the "patient lay summary of results" link at the end of the #adaura presentation was extremely bias and can misinform a patient. if you need a "patient lay" summary, watch this break down of the trial instead: #asco23 
Onkologie PharmD - It's not personal, it's about the data.
Read Malignant and listen to Plenary Session. 
KP - opinions are my own, not my employer’s